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MEDICAL attitudes to psychotropic drugs in general and antidepressants in
particular tend to be casual, and their effects seen as innocuous. Indeed if used
as recommended by their manufacturers tricyclic antidepressants are not very
effective drugs, although some of their side effects and interactions can be very
serious. It has been stated that tricyclics generally have a margin of superiority
over placebos of 20- 30 per cent, and given an average placebo response of 40
per cent in most psychiatric patients, they thus fail in 30 - 40 per cent of cases
(Lehman, 1966). There are a number of factors contributing to this including a
wide individual variation in pharmacokinetics (Alexanderson et al, 1969; Asberg
et al, 1971) and poor patient compliance (Willcox et al, 1965), but perhaps the
most important, although controversial, is the failure to distinguish depression
as an illness from depression as a symptom.
THE ENDOGENOUS-NEUROTIC DISTINCTION
Opposition to an endogenous-neurotic distinction in depressive conditions has
come, for different reasons, from two quarters, viz. academic psychiatry and
drug companies. The Maudsley group from the time of the late Sir Aubrey
Lewis argued that (a) environmental factors could almost invariably be found
in every type of depression if one looked hard enough (Lewis, 1934), and (b)
statistical analyses of case history material (Kendell, 1968) or of data based on
standardised interviews of depressed patients (Kendell and Gourlay, 1970) had
failed to show a clustering of two separate syndromes. The drug companies, on
the other hand, have opposed the distinction presumably because it would limit
the market, particularly if say only 10 -20 per cent of depressed patients were
deemed to suffer from "endogenous" depression. Consequently their products
are often advertised as being effective in both depression (of any type) and anxiety.
Nevertheless many psychiatrists, particularly those working in mental hos-
pitals, daily make a judgment between those depressions which represent an
abnormal personality change and are likely to respond to E.C.T. or tricyclic
drugs, and those which do not, and will not. This distinction has always been
upheld by the Ncwcastle School who developed a rating scale for doing so
(Carney, Roth and Garside, 1965). The North Americans have only recently
joined in this argument and it is interesting that a series of papers based on a
collaborative study involving nine hospitals, supports the endogenous-neurotic
distinction as a predictor of response to antidepressant drugs (Raskin and Crook,
1051976). A recent British statistical review of thirty controlled trials of imipramine
and placebo in the treatment of depressive illness found that only in those
trials where an endogenous-neurotic distinction was made, was imipramine
consistently found to be significantly better than placebo (Rogers and Clay,
1975).
A working compromise is frequently adopted whereby every depression s
seen as having both constitutional and environmental components which are
mutually complementary with regard to aetiological specificity (see Figure 1).
This continuum is based on the ideas of Angst (1974). Kendell, who had also
adopted a similar continuum, has recently made a very helpful and fair review
of the numerous ways of classifying depressions now in use (Kendell, 1976).
The degree to which biological factors appear to be present, and thus the extent
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to which a favourable response to drugs or E.C.T. can be expected, is judged
from the descriptive phenomenology of the presenting symptoms rather than
from the recent history. Thus, on the one hand, diurnal variation in mood,
early morning wakening, loss of appetite, weight, energy and libido are marked
and the environmental factors are seen as non-specific "triggers"; whereas, on
the other, the depression is an understandable reaction, given the previous
personality and the specific prevailing circumstances, and "biological symptoms"
are minimal. In addition to biological symptoms, guilt, remorse, hopelessness,
psychomotor retardation and impaired insight are important aspects of the
mental state in primary depressive illness. Severity probably varies indepen-
dantly in both types of depression and is not of itself indicative of a good response
to drugs, and the terms "deep depression" or "severe depression" are therefore
confusing. Confusion can also arise if too much weight is placed on trying to
assess the specificity of environmental factors, particularly in older age groups,
for such patients are often only too willing to offer "reasons" for feeling miser-
able. The failure to see agitated elderly patients as "depressed", and miserable
106youngsters as primarily "anxious" (or angry), leads to further confusion and
confusing support for the drug companies' claim that antidepressant drugs are
equally effective in anxiety and depression.
DANGERS OF ANTIDEPRESSANT DRUGS
The indiscriminant use of tricyclic antidepressant drugs is not only wasteful
but dangerous. They are among the most toxic of commonly used psychotropic
drugs. In 1973 9 per cent of 2,914 deaths from suicidal, accidental and "un-
determined" poisoning, were attributable to tricyclic drugs (Brewer, 1975). Death
from tricyclic overdose may vary from 5 to 10 per cent of adult cases to nearly
50 per cent in children (Crane, 1970). A correlation between availability and
the frequency of adult self-poisoning has been shown from the poison enquiries
recorded at this department (Elmes, 1977). There is also an unnecessary risk of
cardiac conduction defects, sudden death, anticholinergic effects, and drug
interactions. Jaaskelainen and Viukari (1976) go even further and have argued
that since E.C.T. has been giving way to tricyclic antidepressants in the manage-
ment of depressive illness, there has been an increased length of hispital stay,
decreased degree of recovry, more psychomotor impairment and drug toxicity,
and a greater number of accidents and suicides.
AVAILABILITY OF ANTIDEPRESSANT DRUGS
In the following calculations all tricyclic, bicyclic and tetracyclic antidepres-
sants and monoamine oxidase inhibitors have been included as "antidepressant
drugs", but not L-tryptophan or lithium. Table 1 shows the increasing number
of antidepressant drugs available to general practitioners from 1966-1975. Table
2 shows the increase in the number of drug companies involved. In 1966 7
drug companies were marketing 14 antidepressant preparations containing 7
TABLE 1
1966 1970 1975
Number of Antidepressant Drugs 14 18 21
Number of Antidepressant Drugs 21 32 38
(all strengths)
TABLE 2
1966 1975
Number of companies producing Antidepressant Drugs 7 11
Number having more than 10% share of market 4 3
different drugs; in 1975 this had risen to 11 companies marketing 21 preparations
containing 13 drugs. Figure 2 shows the distribution of these drugs expressed
as percentages of the total prescribed. In 1966 5 preparations covered three
quarters of the market, and 90 per cent of the total market was covered by 4
drug companies; by 1975 10 preparations were competing for the same three
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quarters of the market, and the top 3 companies shared little more than 50
per cent of the total market between them. Thus an a!most 100 per cent
increase in the number of antidepressant drugs available in the last 10 years,
Fig. 3. CHANGES IN THE PRESCRIBING OF ANTIDEPRESSANTS
MARKETED
>4 AFTER 1966
30 AVAILABLE
§ | N 1966
20
In4
1966 1970 1975
108from an increasing number of drug companies, means increased competition for
smaller percentages of the total market. Not surprisingly the net result would
appear to be an expansion in the market. This is illustrated in Figure 3, where
it can be seen that there has been a 100 per cent increase in the number of
tablets for depression issued per day in the same 1966 - 1975 period. Most of
this increase has been due to the introduction of new preparations; the pre-
scribing of preparations available in 1966 being quite similar to their use in 1975.
PRESCRIBING OF ANTIDEPRESSANT DRUGS IN NORTHERN
IRELAND
Figure 4 shows the steady increase in the prescribing of antidepressants in
Northern Ireland between 1966 and 1975, expressed as defined daily doses per
1,000 of population (Elmes, et al, 1976). Amitriptyline is still the single most
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frequently prescribed antidepressant. These figures take no account of the fact
that, apart from their occasional use in eneuretic children, the drugs are pre-
sumably only prescribed for adults (over 15 years). If the figures are adjusted
accordingly it is found that whereas in 1966 4+ adults per thousand were taking
a daily dose of an antidepressant drug, this had more than doubled to 9+ adults
per thousand in 1975.
No publication has been found in the psychiatric literature which suggests
there has been a real increase in primary depressive illness in the past 10 years.
Nor can the increase in the use of antidepressants be attributed to increasing
secondary depression due to our political troub!es, unless the English are more
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depressed by them than we are ourselves (see Figure 5). In fact it has been
shown that there was a reduction in both types of depression in Belfast in the
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11012 months following the outbreak of trouble here (Lyons, 1972). The trend of
increasing antidepressant prescribing is widespread in the western world and
Figure 6 shows that our prescribing of antidepressants is intermediate between
that in Norway and Sweden. The problem of increasing use of phychotropic
drugs in general seems to be world-wide and is no greater in the West than in
the East, nor related to availability of psychotherapy as an alternative (Lall
and Parish, 1975).
DISCUSSION AND CONCLUSIONS
The figures on antidepressant prescribing reflect a complex situation. There
is likely to be an interaction between at least three variables, viz. (a) patients'
increasing demands for and expectations from medical remedies, (b) doctors'
increasing sophistication and awareness of psychological medicine, and (c) the
interest of drug companies in a market of almost unlimited potential. It has
been suggested in this paper that this latter factor can by itself change our use
of these drugs. This is a particularly great liability in an area where there is so
little objectivity in diagnosis or assessment of severity. Clearly the recent in-
crease in antidepressant drug prescribing is not likely to be associated with any
increase in depression as an illness, but rather with the use of these drugs for
depression as a symptom. It is a modern aspect of an old endeavour, that of
trying to treat or ameliorate personal problems with drugs. It is therefore indis-
criminate, unnecessary, unlikely to be effective and potentially dangerous. On
the other hand more careful attention to the proper clinical diagnosis of depres-
sive illness, adequate dosage and patient compliance is likely to improve the
efficacy and predictability of response to antidepressant medications (Knesevich
and Biggs, 1976; Asberg, et al, 1971).
SUMMARY
An analysis of the prescribing of antidepressants in Northern Ireland in the
last decade shows that there has been a 100 per cent increase in the number of
people taking these drugs, to an estimated 9i adults per thousand each day.
This is less likely to be associated with a corresponding increase in either primary
or secondary depression, than with an increasing number of drug companies
manufacturing a greater number of antidepressant preparations.
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